retatrutide peptide trial 🎙️ NEW EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in retatrutide clinical trials weight loss

The observations remain preliminary, and rigorous clinical trials are needed to establish efficacy, optimal dosing, and safety profiles for this potential indication

We propose that GGT may be utilized in public health campaigns, in the research arena, and in clinical practice to identify those individuals who can benefit most from the proactive preventive and therapeutic approaches, given that they are at high cardiometabolic risk

Shi et al., 2024), collectively exacerbating inflammation mediated by the UDPG/P2Y14R axis

Sanjeev Sockalingam, Obesity Canada's scientific director and a professor of psychiatry at the University of Toronto